Cytosorbents Corporation (CTSO): Price and Financial Metrics


Cytosorbents Corporation (CTSO): $1.89

0.02 (+1.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CTSO POWR Grades


  • Value is the dimension where CTSO ranks best; there it ranks ahead of 65.59% of US stocks.
  • The strongest trend for CTSO is in Momentum, which has been heading down over the past 179 days.
  • CTSO ranks lowest in Growth; there it ranks in the 9th percentile.

CTSO Stock Summary

  • With a year-over-year growth in debt of 2,178.21%, Cytosorbents Corp's debt growth rate surpasses 99.22% of about US stocks.
  • Over the past twelve months, CTSO has reported earnings growth of 226.19%, putting it ahead of 90.98% of US stocks in our set.
  • The volatility of Cytosorbents Corp's share price is greater than that of 89.87% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Cytosorbents Corp, a group of peers worth examining would be RCEL, AIRG, TUFN, FLDM, and BNGO.
  • Visit CTSO's SEC page to see the company's official filings. To visit the company's web site, go to www.cytosorbents.com.

CTSO Valuation Summary

  • In comparison to the median Healthcare stock, CTSO's EV/EBIT ratio is 213.65% lower, now standing at -33.3.
  • CTSO's EV/EBIT ratio has moved down 31.7 over the prior 166 months.
  • CTSO's price/sales ratio has moved NA NA over the prior 166 months.

Below are key valuation metrics over time for CTSO.

Stock Date P/S P/B P/E EV/EBIT
CTSO 2021-08-31 9.2 5.6 -40.0 -33.3
CTSO 2021-08-30 9.2 5.6 -40.1 -33.4
CTSO 2021-08-27 8.7 5.3 -38.0 -31.3
CTSO 2021-08-26 8.4 5.1 -36.7 -30.2
CTSO 2021-08-25 8.5 5.1 -36.9 -30.4
CTSO 2021-08-24 8.2 5.0 -35.7 -29.2

CTSO Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -135.49%.
  • Its 2 year cash and equivalents growth rate is now at 25.13%.
  • Its year over year net income to common stockholders growth rate is now at 52.05%.
CTSO's revenue has moved up $20,394,642 over the prior 34 months.

The table below shows CTSO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 43.16553 -14.0056 -24.55865
2021-09-30 44.33911 -9.571806 -15.92936
2021-06-30 45.1253 -8.722604 -10.3628
2021-03-31 42.89614 -4.748183 -8.55223
2020-12-31 41.0046 -5.613286 -7.837188
2020-09-30 36.47914 -8.679693 -11.10882

CTSO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTSO has a Quality Grade of D, ranking ahead of 21.38% of graded US stocks.
  • CTSO's asset turnover comes in at 0.475 -- ranking 101st of 186 Medical Equipment stocks.
  • NVCR, CUTR, and HAE are the stocks whose asset turnover ratios are most correlated with CTSO.

The table below shows CTSO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.475 0.759 -0.637
2021-03-31 0.518 0.734 -0.733
2020-12-31 0.570 0.730 -0.516
2020-09-30 0.648 0.709 -0.613
2020-06-30 0.857 0.706 -0.892
2020-03-31 0.884 0.719 -0.911

CTSO Price Target

For more insight on analysts targets of CTSO, see our CTSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.60 Average Broker Recommendation 1.33 (Strong Buy)

CTSO Stock Price Chart Interactive Chart >

Price chart for CTSO

CTSO Price/Volume Stats

Current price $1.89 52-week high $9.80
Prev. close $1.87 52-week low $1.78
Day low $1.83 Volume 151,300
Day high $1.97 Avg. volume 211,912
50-day MA $2.59 Dividend yield N/A
200-day MA $4.89 Market Cap 82.33M

Cytosorbents Corporation (CTSO) Company Bio


CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.


CTSO Latest News Stream


Event/Time News Detail
Loading, please wait...

CTSO Latest Social Stream


Loading social stream, please wait...

View Full CTSO Social Stream

Latest CTSO News From Around the Web

Below are the latest news stories about Cytosorbents Corp that investors may wish to consider to help them evaluate CTSO as an investment opportunity.

Cytosorbents (CTSO) Presents At Annual SVB Leerink Global Health Conference

The following slide deck was published by Cytosorbents Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | February 24, 2022

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022. CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.

Yahoo | February 8, 2022

CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.

Yahoo | February 3, 2022

CytoSorbents says patient enrollment begins in PROCYSS trial of CYtoSorb for septic shock

CytoSorbents (NASDAQ:CTSO) said the first patient was enrolled in the PROCYSS trial evaluating CYtoSorb to reverse refractory septic shock (RSS). RSS is a persistent and potentially fatal drop in blood pressure despite fluid resuscitation and high dose vasopressor use, seen in patients with life-threatening infection and sepsis. The company said...

Seeking Alpha | February 1, 2022

First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the PROCYSS (Prospective, Randomized, controlled trial with use Of CYtoSorb® to reverse refractory Septic Shock) trial in Germany by Prof. Dr. Stefan Kluge, Director, Department of Intensive Care Medicine at the Univers

Yahoo | February 1, 2022

Read More 'CTSO' Stories Here

CTSO Price Returns

1-mo -26.74%
3-mo -50.13%
6-mo -60.21%
1-year -76.81%
3-year -71.36%
5-year -56.55%
YTD -54.89%
2021 -47.43%
2020 107.01%
2019 -52.35%
2018 24.31%
2017 19.27%

Continue Researching CTSO

Want to see what other sources are saying about Cytosorbents Corp's financials and stock price? Try the links below:

Cytosorbents Corp (CTSO) Stock Price | Nasdaq
Cytosorbents Corp (CTSO) Stock Quote, History and News - Yahoo Finance
Cytosorbents Corp (CTSO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.797 seconds.